View Item 

Show simple item record

Oral health‐related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments
dc.contributor.authorTaichman, L. Susan
dc.contributor.authorPoznak, Catherine H.
dc.contributor.authorInglehart, Marita R.
dc.date.accessioned2018-02-05T16:33:41Z
dc.date.available2019-03-01T21:00:17Zen
dc.date.issued2018-01
dc.identifier.citationTaichman, L. Susan; Poznak, Catherine H.; Inglehart, Marita R. (2018). "Oral health‐related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments." Special Care in Dentistry 38(1): 36-45.
dc.identifier.issn0275-1879
dc.identifier.issn1754-4505
dc.identifier.urihttps://hdl.handle.net/2027.42/141444
dc.description.abstractAimThe objectives are to compare responses of breast cancer (BCa) treatment groups (chemotherapy, tamoxifen, and aromatase inhibitors (AIs) to each other and a control regarding (a) subjective oral health, (b) oral health‐related behaviors, (c) oral health‐related concerns, and (d) communication with health care providers.MethodsSurvey data were collected from 140 postmenopausal BCa patients and 41 healthy postmenopausal control respondents.ResultsBCa patients reported on average more frequent mouth sores/mucositis (5‐point scale with 1 = never: 1.63 vs. 1.14; p < .01), glossadynia (1.60 vs. 1.07; p < .01), xerostomia (2.48 vs. 1.40; p < .01), and dysgeusia (2.10 vs. 1.46; p < .01) than the control respondents. Patients undergoing chemotherapy were more aware that cancer treatment can affect their oral health than patients on tamoxifen/AI (93% vs. 55%/56%; p < .001). BCa patients reported being more frequently informed by oncologists about oral health‐related effects of cancer treatment than by dentists. Oncologists/nurses were more likely to communicate about oral health‐related treatment effects with patients undergoing chemotherapy than patients on tamoxifen or AIs. Few BCa patients perceived dentists as knowledgeable about cancer treatment‐related oral concerns and trusted them less than oncologists.ConclusionsBCa treatments impact oral health. Low percentages of BCa patients had received specific information about impacts of BCa treatments on oral health from their dentists.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherantiestrogen medication
dc.subject.otherchemotherapy
dc.subject.otherpost menopause
dc.subject.otheroral health
dc.subject.otherbreast neoplasms
dc.titleOral health‐related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141444/1/scd12266.pdf
dc.identifier.doi10.1111/scd.12266
dc.identifier.sourceSpecial Care in Dentistry
dc.identifier.citedreferenceSaad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active‐controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23 ( 5 ): 1341 ‐ 7.
dc.identifier.citedreferenceDunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007; 9 ( 1 ): R6.
dc.identifier.citedreferenceJensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brunner N, Nauntofte B. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106 ( 2 ): 217 ‐ 26.
dc.identifier.citedreferenceRaber‐Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Onco 2010; 46 ( 6 ): 452 ‐ 6.
dc.identifier.citedreferenceAl‐Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber‐Durlacher JE. Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2015; 2 ( 4 ): 202 ‐ 11.
dc.identifier.citedreferenceBarroso‐Sousa R, Santana IA, Testa L, de Melo Gagliato D, Mano MS. Biological therapies in breast cancer: common toxicities and management strategies. Breast 2013; 22 ( 6 ): 1009 ‐ 18.
dc.identifier.citedreferenceSonis ST, Fey EG. Oral complications of cancer therapy. Oncology 2002; 16 ( 5 ): 680 ‐ 6.
dc.identifier.citedreferenceYuan A, Sonis S. Emerging therapies for the prevention and treatment of oral mucositis. Expert Opin Emerg Drugs 2014; 19 ( 3 ): 343 ‐ 51.
dc.identifier.citedreferenceTaichman LS, Inglehart MR, Giannobile WV, Braun T, Kolenic G, Van Poznak C. Periodontal health in women with early‐stage postmenopausal breast cancer newly on aromatase inhibitors: a pilot study. J Clin Periodontol 2015; 86 ( 7 ): 906 ‐ 16.
dc.identifier.citedreferenceEagle I, Benavides E, Eber R, et al. Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis. J Clin Periodontol 2016; 43 ( 8 ): 659 ‐ 67.
dc.identifier.citedreferenceTaichman LS, Van Poznak CH, Inglehart MR. Self‐reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis. Support Care Cancer 2016; 24 ( 11 ): 4815 ‐ 24.
dc.identifier.citedreferenceMosel DD, Bauer RL, Lynch DP, Hwang ST. Oral complications in the treatment of cancer patients. Oral Dis 2011; 17 ( 6 ): 550 ‐ 9.
dc.identifier.citedreferenceStreckfus CF, Baur U, Brown LJ, Bacal C, Metter J, Nick T. Effects of estrogen status and aging on salivary flow rates in healthy Caucasian women. Gerontology 1998; 44 ( 1 ): 32 ‐ 9.
dc.identifier.citedreferenceMigliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011; 7 ( 1 ): 34 ‐ 42.
dc.identifier.citedreferenceSahin S, Karatas F, Sever AR, Altundag K. Current management of aromatase inhibitor‐induced arthralgia. J BUON 2016; 21 ( 1 ): 17 ‐ 20.
dc.identifier.citedreferenceTaichman LS, Gomez G, Inglehart MR. Oral health‐related complications of breast cancer treatment: assessing dental hygienists’ knowledge and professional practice. J Dent Hyg 2015; 89 ( Suppl 2 ): 22 ‐ 37.
dc.identifier.citedreferenceEpstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012; 62 ( 6 ): 400 ‐ 22.
dc.identifier.citedreferenceEpstein JB, Parker IR, Epstein MS, Gupta A, Kutis S, Witkowski DM. A survey of national cancer institute‐designated comprehensive cancer centers’ oral health supportive care practices and resources in the USA. Support Care Cancer 2007; 15 ( 4 ): 357 ‐ 62.
dc.identifier.citedreferenceEpstein JB, Parker IR, Epstein MS, Stevenson‐Moore P. Cancer‐related oral health care services and resources: a survey of oral and dental care in Canadian cancer centres. J Can Dent Assoc 2004; 70 ( 5 ): 302 ‐ 4.
dc.identifier.citedreferenceTaichman LS, Griggs JJ, Inglehart MR. Periodontal health, perceived oral health, and dental care utilization of breast cancer survivors. J Pub Health Dent 2015; 75 ( 2 ): 148 ‐ 56.
dc.identifier.citedreferenceRathbone EJ, Brown JE, Marshall HC, et al. Osteonecrosis of the jaw and oral health‐related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol 2013; 31 ( 21 ): 2685 ‐ 91.
dc.identifier.citedreferenceAmerican Cancer Society. Breast cancer facts & figures 2015–2016. Atlanta, GA. Available from https://www.cancer.org/research/cancer‐facts‐statistics/breast‐cancer‐facts‐figures.html. Accessed December 5th, 2017.
dc.identifier.citedreferenceCarlson RW, Brown E, Burstein HJ, et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4 ( Suppl 1 ): S1 ‐ 26.
dc.identifier.citedreferenceCarlson RW, Moench S, Hurria A, et al. NCCN task force report: breast cancer in the older woman. J Natl Compr Canc Netw 2008; 6 ( Suppl 4 ):S1‐25.quiz S26 ‐ 7.
dc.identifier.citedreferenceEarly Breast Cancer Trialist’s Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomised trials. Lancet 2005; 365 ( 9472 ): 1687 ‐ 717.
dc.identifier.citedreferenceBedard PL, Cardoso F. Can some patients avoid adjuvant chemotherapy for early‐stage breast cancer? Nat Rev Clin Oncol 2011; 8 ( 5 ): 272 ‐ 9.
dc.identifier.citedreferencePiccart‐Gebhart MJ. New developments in hormone receptor‐positive disease. Oncologist 2010; 15 ( Suppl 5 ): 18 ‐ 28.
dc.identifier.citedreferenceHarvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand‐binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17 ( 5 ): 1474 ‐ 81.
dc.identifier.citedreferenceRastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori 2008; 94 ( 3 ): 370 ‐ 83.
dc.identifier.citedreferenceZhao H, Hei N, Wu Y, et al. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer 2017; 123 ( 6 ): 940 ‐ 47.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
scd12266.pdf
Size:
134.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.